Hereditary Angioedema Treatment Market Size, Share, Growth Analysis, By Drug class(C1-esterase inhibitor, Brandykinin B2 receptor antagonist, Kallikrein inhibitor, others), By Treatment(Prophylaxis, On-demand), By Route of administration(Intravenous, Subcutaneous, Oral), By Distribution channel(Hospital pharmacy, Retail Pharmacy), By Application(Prophylaxis and Treatment), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35J2031 | Region: Global | Published Date: February, 2024
Pages: 157 |Tables: 141 |Figures: 77

Hereditary Angioedema Treatment Market Insights

Hereditary Angioedema Treatment Market size was valued at USD 2.65 billion in 2019 and is poised to grow from USD 2.72 billion in 2023 to USD 10.39 billion by 2031, growing at a CAGR of 2.56% in the forecast period (2024-2031).

The key factor driving market expansion is the increased acknowledgment of treating rare disorders such as hereditary angioedema (HAE). According to the National Organization for Rare Disorders (NORD), the scenario is estimated to affect around 1 in 50,000 persons, with this illness affecting 1 in 150,000 people worldwide. Angioedema attacks are characterised by abrupt, often severe swelling in several areas of the body, including the abdomen, limbs, throat, and face. Many organisations are raising awareness about the diseases and their treatments, such as the US Hereditary Angioedema Association, a non-profit organisation dedicated to providing HAE sufferers with access to cutting-edge remedy alternatives and dependable, private help to deal with symptoms.

According to a survey done in the United States, physicians indicated improvements in HAE care in recent years, according to the study. Due to recent therapeutic improvements, documented cases of HAE have improved, reducing anxiety about adverse treatment effects, and high levels of patient satisfaction have been noted. According to a July 2020 paper titled 'Spectrum of diagnosis of hereditary angioedema: Seven case reports,' roughly 30,000-50,000 persons in India are affected. Dermatologists, gastroenterologists, and clinical allergists handle the majority of cases.

US Hereditary Angioedema Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 2.65 billion

Largest Segment

Intravenous

Fastest Growth

Intravenous

Growth Rate

2.56% CAGR

Global Hereditary Angioedema Treatment Market, 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Hereditary Angioedema Treatment Market Segmental Analysis

Hereditary Angioedema Treatment Market is segmented based on drug class, treatment type, route of administration, distribution channel, application, and region. Based on drug class, the Hereditary Angioedema Treatment Market is segmented into C1-esterase inhibitor, Brandykinin B2 receptor antagonist, Kallikrein inhibitor, others. Based on treatment, the Hereditary Angioedema Treatment Market is divided into prophylaxis, on demand. Based on route of administration, the Hereditary Angioedema Treatment Market is segmented into Intravenous, subcutaneous, oral. Based on distribution channel, the Hereditary Angioedema Treatment Market is segmented into hospital pharmacy, retail pharmacy. Based on application, the Hereditary Angioedema Treatment Market is segmented into Prophylaxis and treatment. Based on region, the market is segmented into North America, Asia Pacific, Europe, Latin America, and MEA.

Hereditary Angioedema Treatment Market Analysis by Drug Class:

The market is divided into C1-esterase inhibitors, Kallikrein inhibitors, B2 bradykinin receptor antagonists, and additional medications such as attenuated androgens and tranexamic acid based on drug class. C1-esterase inhibitors were the most profitable sector. The products' dominance in the market is related to their use in both on-demand and preventative treatment of HAE.

Hereditary Angioedema Treatment Market Analysis by Route of Administration:

The hereditary angioedema treatment market has been segmented into intravenous, subcutaneous, and oral administration routes. In terms of revenue, the intravenous treatments segment led the market. Existing therapies for HAE management are mostly administered intravenously, which has contributed significantly to its growth.

Intravenously administered therapies have long been the mainstay of treating patients with hereditary angioedema. Patients, on the other hand, have limited vascular access, restricting the administration of recurrent IV medicines. Other dangers linked with the implantation of long-term catheters for therapy include thrombosis and infection. Furthermore, patients face difficulties when receiving intravenous medicines on a regular basis, lowering treatment compliance.

Global Hereditary Angioedema Treatment Market By Route of Administration , 2021(%)

To get detailed analysis on other segments, Request For Free Sample Report

Hereditary Angioedema Treatment Market Regional Insights

North America dominated the global hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.

Due to increased patient awareness, Asia-Pacific is expected to dominate the global market. The rest of the world is expected to be a highly profitable in the market during the forecast period, owing to factors such as an increase in the number of reported cases of hereditary angioedema in recent times, increased awareness of rare diseases in developing countries, and the introduction of novel therapies.

Global Hereditary Angioedema Treatment Market By Geography, 2021 - 2028
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Hereditary Angioedema Treatment Market Dynamics

Hereditary Angioedema Treatment Market Drivers

Increased Emphasis on Advanced Therapeutics

  • Researchers and manufacturers around the world are increasing their focus on advanced therapeutics for the treatment of hereditary angioedema disorders and taking the necessary steps to create or advance therapeutics for the treatment of hereditary angioedema disorders. Several manufacturers have recently filed new medication applications in various counties for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor treatment of Type I, Type II, and Type III HAE. The increased emphasis on sophisticated treatments and innovative drug applications will increase the availability of hereditary angioedema treatment therapies during the forecast period.
  • Its increased awareness and the rise in the occurrence of rare conditions around the world are important factors driving the global market. Novel medicine approvals in recent years, as well as promising pipeline drugs, have fuelled the expansion of the global market. Furthermore, the increased severity of severe edema attacks caused by elevated oestrogen levels, as well as the increased use of ACE inhibitors, are driving the expansion of the hereditary angioedema treatment market.

Hereditary Angioedema Treatment Market Restraint

  • Misdiagnosis of the ailment as common allergies, appendicitis, and irritable bowel syndrome has caused treatment to be halted, hampering the growth of the hereditary angioedema treatment market. Lack of awareness regarding HAE is a primary cause of misdiagnosis, which leads to suboptimal treatment for patients. The majority of people with hereditary angioedema are misdiagnosed for appendicitis, gastrointestinal diseases, and other non-allergic angioedema. A large number of patients have been misdiagnosed with the illness.

Request Free Customization of this report to help us to meet your business objectives.

Hereditary Angioedema Treatment Market Competitive Landscape

The global hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge.

Top Players in the Global Hereditary Angioedema Treatment Market

  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • BioCryst Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Ionis Pharmaceuticals, Inc.
  • Biogen Inc.
  • Sanofi S.A.
  • Shire plc (acquired by Takeda in 2019)
  • KalVista Pharmaceuticals, Inc.
  • Dyax Corp. (acquired by Shire in 2016)
  • Adverum Biotechnologies, Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • Catalyst Biosciences, Inc.
  • Attune Pharmaceuticals, Inc.
  • RUCONEST (Pharming Group N.V.)
  • Haegarda (CSL Limited)
  • Firazyr (Shire plc)

Hereditary Angioedema Treatment Market Recent Developments

  • In April 2022, Takeda Pharmaceutical Company Limited., a research-based global company, announced that TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe was available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older
  • On June 6, 2022, BioCryst Pharmaceuticals, Inc., a company that designs and develops small molecule medicines for rare diseases like hereditary angioedema (HAE) and fibrodysplasia ossificans progressive (FOP), announced that Health Canada had approved oral, once-daily ORLADEYO (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.

Hereditary Angioedema Treatment Key Market Trends

  • Rising awareness of rare conditions and hereditary angioedema in recent years can be credited to the expansion of the global market. The primary factors driving the global market include novel therapeutics, pipeline medications, and new product launches such as Takhzyro, a lanadelumab monoclonal antibody for the treatment of prophylactic HAE. The majority of pipeline medications are oral, due to which the oral method of administration is growing as a trend in the market. This approach is more convenient for patients and has fewer adverse effects. Companies are attempting to get into the rare illnesses industry with novel products in the pipeline. Due to the market expiration, these players may enter the hereditary angioedema treatment market.

Hereditary Angioedema Treatment Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our market analysis, the global hereditary angioedema treatment market is expected to expand at a healthy rate during the projected period, owing to growing awareness and diagnosis of uncommon genetic illnesses, as well as product innovation for their treatment. Subcutaneous injections are becoming more popular due to patient convenience and ease, which has been aided by the introduction of innovative new products that use this route of administration. Due to the enormous number of reported cases and a well-established healthcare infrastructure, the North American regional market is likely to grow rapidly. Manufacturers concentrating on improving their product offerings and include tailored and specialty medications for the treatment of hereditary angioedema.

Report Metric Details
Market size value in 2023 USD 2.65 billion
Market size value in 2031 USD 10.39 billion
Growth Rate 2.56%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Drug class
    • C1-esterase inhibitor, Brandykinin B2 receptor antagonist, Kallikrein inhibitor, others
  • Treatment
    • Prophylaxis, On-demand
  • Route of administration
    • Intravenous, Subcutaneous, Oral
  • Distribution channel
    • Hospital pharmacy, Retail Pharmacy
  • Application
    • Prophylaxis and Treatment
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • BioCryst Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Ionis Pharmaceuticals, Inc.
  • Biogen Inc.
  • Sanofi S.A.
  • Shire plc (acquired by Takeda in 2019)
  • KalVista Pharmaceuticals, Inc.
  • Dyax Corp. (acquired by Shire in 2016)
  • Adverum Biotechnologies, Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • Catalyst Biosciences, Inc.
  • Attune Pharmaceuticals, Inc.
  • RUCONEST (Pharming Group N.V.)
  • Haegarda (CSL Limited)
  • Firazyr (Shire plc)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Hereditary Angioedema Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Hereditary Angioedema Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Hereditary Angioedema Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Hereditary Angioedema Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Hereditary Angioedema Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Hereditary Angioedema Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Hereditary Angioedema Treatment Market size was valued at USD 2.65 billion in 2019 and is poised to grow from USD 2.72 billion in 2023 to USD 10.39 billion by 2031, growing at a CAGR of 2.56% in the forecast period (2024-2031).

The hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge. 'CSL Limited', 'Takeda Pharmaceutical Company Limited', 'BioCryst Pharmaceuticals, Inc.', 'Pharming Group N.V.', 'Ionis Pharmaceuticals, Inc.', 'Biogen Inc.', 'Sanofi S.A.', 'Shire plc (acquired by Takeda in 2019)', 'KalVista Pharmaceuticals, Inc.', 'Dyax Corp. (acquired by Shire in 2016)', 'Adverum Biotechnologies, Inc.', 'Amgen Inc.', 'Arrowhead Pharmaceuticals, Inc.', 'BioMarin Pharmaceutical Inc.', 'Catalyst Biosciences, Inc.', 'Attune Pharmaceuticals, Inc.', 'RUCONEST (Pharming Group N.V.)', 'Haegarda (CSL Limited)', 'Firazyr (Shire plc)'

Researchers and manufacturers around the world are increasing their focus on advanced therapeutics for the treatment of hereditary angioedema disorders and taking the necessary steps to create or advance therapeutics for the treatment of hereditary angioedema disorders. Several manufacturers have recently filed new medication applications in various counties for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor treatment of Type I, Type II, and Type III HAE. The increased emphasis on sophisticated treatments and innovative drug applications will increase the availability of hereditary angioedema treatment therapies during the forecast period.

Rising awareness of rare conditions and hereditary angioedema in recent years can be credited to the expansion of the market. The primary factors driving the market include novel therapeutics, pipeline medications, and new product launches such as Takhzyro, a lanadelumab monoclonal antibody for the treatment of prophylactic HAE. The majority of pipeline medications are oral, due to which the oral method of administration is growing as a trend in the market. This approach is more convenient for patients and has fewer adverse effects. Companies are attempting to get into the rare illnesses industry with novel products in the pipeline. Due to the market expiration, these players may enter the hereditary angioedema treatment market.

North America dominated the hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Hereditary Angioedema Treatment Market

Report ID: SQMIG35J2031

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE